Background
==========

Canonical Wnt signaling is induced by the binding of Wnt ligands to cell surface receptors, resulting in the inactivation of intact Axin 1-containing complexes \[[@B1]\], and accumulation of transcriptionally active beta-catenin \[[@B1]-[@B5]\] which interacts with Tcf DNA binding proteins \[[@B6]-[@B11]\]. Beta-catenin-Tcf transcriptional complexes drive transcription from Tcf site-containing promoters, including both reporter constructs and endogenous Wnt responsive genes containing Tcf/Lef sites \[[@B8],[@B9]\] and refs. therein. Constitutively active Wnt signaling, caused by mutations in the *APC* and *beta-catenin* genes \[[@B8]-[@B10]\] promotes colonic cell proliferation and tumorigenesis; however, both relatively high and relatively low levels of Wnt transcriptional activity lead to CRC cell apoptosis \[[@B12]-[@B16]\].

Colorectal cancer (CRC) may to some extent be preventable through diet \[[@B13],[@B14],[@B17]-[@B22]\]. The protective action of dietary fiber against CRC has been attributed to its fermentation in the colon, producing the histone deacetylase inhibitor (HDACi) butyrate \[[@B23],[@B24]\]. HDACis induce cell cycle arrest, differentiation, and/or apoptosis of CRC cells \[[@B25],[@B26]\]; the HDACis butyrate and trichostatin A (TSA), which induce apoptosis in CRC cells *in vitro*, hyperactivate Wnt transcriptional activity in these cells \[[@B12]-[@B14]\]. The ability of butyrate, and other HDACis, to promote CRC apoptosis and repress cell growth, is casually related to the degree of Wnt hyperactivation induced by these agents \[[@B12]-[@B14]\].

To determine the genetic program regulated by butyrate-mediated Wnt hyperactivation, we performed total human microarray analysis on HCT-116 CRC cells. Cells were treated with a physiologically relevant concentration (5 mM) of butyrate \[[@B24]\] or left untreated. To evaluate changes in Wnt-specific gene expression, Wnt activity was suppressed with inducible dominant negative Tcf4 (DN-Tcf4), which competes with endogenous beta-catenin-Tcf (BCT) complexes for binding to promoter sequences of Wnt target genes \[[@B8]\]. We identified more than one thousand genes that exhibited Wnt-specific changes in expression (\>two-fold, P \< 0.01) after exposure to butyrate. These changes in gene expression include a variety of gene families, representing clusters of functionally related gene products.

Thus, in this short Research Article/Data Note, we identify, for the first time, in a human CRC cell line, how exposure to butyrate modulates the expression of genes that are direct or indirect targets of Wnt signaling.

Methods
=======

Plasmids, cell lines, transfection, luciferase assay
----------------------------------------------------

pTOPFLASH (TOP), pFOPFLASH (FOP), and inducible DN-Tcf4 were from Dr. H. Clevers (UMC Utrecht, Utrecht, Netherlands). Tet repressor plasmid was from Invitrogen (Carlsbad, CA). HCT-116 cells were obtained from the American Type Culture Collection (ATCC). Transfection with lipofectamine 2000 and luciferase assays were performed as previously described \[[@B12]-[@B14]\]. Measurements of Wnt transcriptional activity were performed with the TOP/FOP luciferase reporter system that has wild-type (TOP) or mutant (FOP) Tcf binding sites upstream of a minimal c-fos promoter (8, 9).

Nucleofection and stable transfection
-------------------------------------

Standard protocol was utilized according to manufacturer's instructions. Setting D-32 was used to nucleofect HCT-116 cells. Routinely, 2 μg of DNA and 1 × 10^6^ cells were used per well (6 well plate) for each nucleofection. HCT-116 cells were stably transfected, via nucleofection, with a vector for Tet repressor and a Tet-inducible DN-Tcf4 vector \[[@B27],[@B28]\]. Cells were selected with 100 μg/ml zeocin and 5 μg/ml blasticidin, and DN-Tcf4 expression was induced by doxycycline (4 μg/ml), followed by clonal selection. Clones were assayed based on doxycycline-inducible suppression of Wnt activity as measured by reporter assays, and expression of DN-Tcf4 as evaluated by western blot analysis.

Genus biosystems total human genome microarray analysis
-------------------------------------------------------

After treatment with or without 4 μg/ml doxycycline and then cotreatment with or without 5 mM sodium butyrate (NaB) for 17.5 hr, cells were washed with 1 × PBS, scraped into PBS and pelleted; the pellets were snap frozen in liquid nitrogen and sent to Genus Biosystems (Northbrook, IL) for RNA extraction and microarray analyses, utilizing the Agilent human whole genome oligo microarray. Briefly, RNA extraction and array analyses were performed by Genus as follows. RNA was extracted and purified with Ambion Ribopure isolation, with RNA quality assessed by an Agilent Bioanalyzer. Following first and second strand cDNA synthesis, cRNA target was prepared, fragmented to a uniform size, and hybridized to Agilent Human v2 GE 4x44K arrays. Slides were subsequently washed and scanned on an Agilent G2565 Microarray Analyzer and the resulting data were analyzed with Agilent Feature Extraction and GeneSpring GX v7.3.1 software. A total of six biological replicates of the experiment were performed.

Western blotting
----------------

Anti-FLAG antibody (Origene, Rockville, MD) was used to detect the FLAG-tagged DN-Tcf4. Actin was used a loading control using anti-actin antibody (Sigma, St. Louis, MO). Protein isolation and western blotting were performed as previously described \[[@B12]-[@B14]\].

Statistics
----------

For gene transfection experiments, Students *t*-test was utilized, with statistical significance set at P \< 0.05 for the Wnt reporter experiments. For microarray analyses, paired *T*-test was used at P \< 0.01 and P \< 0.05.

Results and discussion
======================

Characterization of system
--------------------------

We have established that physiologically relevant concentrations of butyrate induce apoptosis, and repress clonal growth, in CRC cells dependent upon the hyperactivation of Wnt activity \[[@B12]-[@B14]\]. Therefore, it is likely that a set of Wnt signaling targeted genes mediates the high apoptotic response of CRC cells to butyrate. To better evaluate differences in gene expression that contribute to the butyrate response, we determined the pattern of gene expression changes due to butyrate treatment, focusing on genes which are direct or indirect Wnt targets. We identified these genes by microarray analyses of HCT-116 cells, in which Wnt signaling is suppressed. Thus, we established a stably transfected HCT-116 cell line expressing doxycycline-inducible DN-Tcf4. DN-Tcf4 is a form of Tcf4 that lacks the beta-catenin interaction domain and represses Wnt activity by competing with BCT complexes for access to DNA binding sites in Wnt target genes (8). We have previously shown that DN-Tcf4 efficiently represses the upregulation of Wnt activity by butyrate in a variety of CRC cell lines, including HCT-116 (\[[@B12]-[@B14]\] and data not shown).

In the stably transfected cell clone, induction with doxycycline repressed the ability of butyrate to upregulate Wnt activity, as expected (Figure [1](#F1){ref-type="fig"}A, B). Wnt activity was measured by luciferase reporter assays, comparing the expression from a Wnt-sensitive reporter (pTOPFLASH) to that of the control reporter that is not responsive to Wnt signaling (pFOPFLASH) (\[[@B12]-[@B14]\] and refs. therein). Untreated cells exhibited a TOP/FOP ratio, indicative of Wnt activity, of 5.5 which was increased to 106.0 (P \< 0.002) by treatment with 5 mM butyrate. Treatment with doxycycline alone resulted in a TOP/FOP ratio of 2.5, which was increased to 4.7 with combinatorial treatment with both doxycycline and butyrate (P \< 0.05). Thus, the fold-upregulation of Wnt activity by butyrate in the presence of doxycycline was approximately 10-fold lower (P \< 0.001) than in the absence of doxycycline.

![**Clone 19 exhibits doxycycline-induced downregulation of the Wnt hyperactivation by butyrate. (A)** Cells were transfected with TOPFlash or FOPFlash reporters and pRLTK (to control for transfection efficiency) and expression of DN-Tcf4 was induced by treatment with 4 μg/ml doxycycline; cells were also treated or not treated with 5 mM butyrate (NaB), both agents (DoxyNaB); control (Ctl) cells were not treated with either agent. After 17 hr of butyrate treatment, Wnt transcriptional activity was measured via luciferase assays. T/F represents the ratio of expression of TOPFlash (wild-type Wnt-responsive promoter) compared to FOPFlash (mutant promoter), measuring overall canonical Wnt activity. **(B)** Data from (A) represented by the fold-upregulation of Wnt activity in the presence (DoxyNaB/Doxy) or absence (NaB/Ctl) of doxycycline. (A) and (B) show data from four independent experiments. Bars, SDs. \* = statistical significance.](1756-0500-7-226-1){#F1}

Consistent with our previous findings with stable transfection of inducible DN-Tcf4 in DLD-1 CRC cells, and transient transfection of this vector in HCT-116 cells \[[@B13]\], basal expression of stably transfected DN-Tcf4 is minimal in the presence of doxycycline and absence of butyrate, but is at high levels in the presence of both agents (Figure [2](#F2){ref-type="fig"}). The likely reason for low basal levels of DN-Tcf4 in the absence of butyrate is counter-selection during clonal selection; clones that would express high levels of DN-Tcf4 in the presence of doxycycline and absence of butyrate would also likely express lower, but physiologically relevant, levels of DN-Tcf4 in the absence of doxycycline. This background expression would likely inhibit cell growth during clonal expansion compared to clones exhibiting lower DN-Tcf4 expression. Given the ability of butyrate to upregulate induced DN-Tcf4 expression in these cells, the relative repression of DN-Tcf4 expression in the absence of butyrate may involve **(a)** histone deacetylation of the DN-Tcf4 promoter sequences, which is reversed by the HDACi activity of butyrate; and/or **(b)** repressed expression of activating transcription factors or enhanced expression of transcriptional repressors, both targeting the DN-Tcf4 promoter. In the latter case, butyrate would be expected to favor DN-Tcf4 transcriptional activation through altered expression of these transcriptional factors.

![**Overexpression of DN-Tcf4 in induced HCT-116 cells.** A stably transfected clone of HCT-116 cells was treated with 4 μg/ml doxycycline (Doxy) and/or 5 mM NaB for 17.5 hr or left untreated. Protein was isolated, and DN-Tcf4 detected with anti-FLAG antibody in western blot analysis. Actin was analyzed as a control. Duplicate samples from a representative western blot shown.](1756-0500-7-226-2){#F2}

Given that combinatorial treatment of cells with doxycycline and butyrate results in high expression of the Wnt inhibitor DN-Tcf4 (Figure [2](#F2){ref-type="fig"}), why does the combination of these two agents result in an increase in the TOP/FOP ratio compared to doxycycline alone (Figure [1](#F1){ref-type="fig"}A)? Butyrate increases the TOP/FOP ratio in CRC cells through the marked hyperactivation of Wnt signaling \[[@B12]-[@B14]\]. In the absence of DN-Tcf4 expression, the TOP/FOP ratio is increased from 5.5 to 106 by butyrate treatment (NaB vs. Ctl in Figure [1](#F1){ref-type="fig"}A). This extremely large activation of Wnt activity is not completely eliminated by the presence of DN-Tcf4. Thus, a modest 1.9-fold increase in the TOP/FOP ratio, from 2.5 to 4.7, is observed upon doxycycline/butyrate cotreatment compared to doxycycline alone (DoxyNaB vs. Doxy in Figure [1](#F1){ref-type="fig"}A).

However, the main experimental comparison for our microarray analyses was that of **(a)** butyrate treatment alone compared to control (NaB/Ctl) vs. **(b)** doxycycline and butyrate treatment compared to doxycycline alone (DoxyNaB/Doxy). Thus, the small upregulation of Wnt activity still induced by butyrate in the presence of DN-Tcf4 expression (1.9-fold) is an order of magnitude less (P \< 0.001) than that induced by butyrate in the absence of DN-Tcf4 (19.3-fold) (compare NaB/Ctl to DoxyNaB/Doxy in Figure [1](#F1){ref-type="fig"}B). This 10-fold difference in Wnt hyperactivation by butyrate observed +/− DN-Tcf4 allows us to identify changes in Wnt-target gene expression induced by butyrate.

The observed expression pattern of DN-Tcf4 (Figure [2](#F2){ref-type="fig"}) is favorable, since the objective was to compare gene expression in the presence or absence of butyrate-enhanced Wnt signaling. Thus, we aimed at repressed Wnt activity upon butyrate treatment; this aim was achieved, as demonstrated by the markedly reduced Wnt hyperactivation shown in Figure [1](#F1){ref-type="fig"}.

We expected that known Wnt activity-targeted genes would exhibit reduced gene expression in the presence of induced DN-Tcf4, and this was confirmed. Table [1](#T1){ref-type="table"} shows the relative expression of selected Wnt/Tcf targeted genes \[[@B27]-[@B29]\]; some of these genes were previously shown to exhibit repressed expression in the presence of induced DN-Tcf4 in LS174T and DLD-1 CRC cells \[[@B27],[@B28]\]. Relative expression levels are shown, after induction with doxycycline alone (Doxy) compared to untreated control (Ctl), or after induction and butyrate treatment (Doxy + NaB) compared to butyrate treatment alone (NaB). Induction with doxycycline alone resulted in moderate to no change in the expression of these genes, while the combination of doxycycline induction and butyrate treatment resulted in statistically significant downregulation. Therefore, as expected, expression of Wnt activity-targeted genes is downregulated upon the high induction of DN-Tcf4 observed after treatment of cells with doxycycline and butyrate.

###### 

Relative expression of Wnt/Tcf-targeted genes upon doxycycline induction in the presence or absence of butyrate

   **Relative expression of Wnt/Tcf-targeted genes**           
  --------------------------------------------------- -------- --------
                         Axin2                         *0.66*   *0.17*
                         BMP4                          *0.79*   *0.40*
                         C-Myc                          1.05    *0.35*
                       Cyclin D1                        1.03    *0.50*
                         Dkk1                           0.88    *0.33*
                         KITLG                          0.91    *0.44*
                         Sox2                           0.78    *0.62*
                         Sox4                           0.93    *0.65*
                         Sox9                          *1.21*   *0.60*
                          SP5                           0.86    *0.29*
                       Vimentin                         1.18    *0.71*

Numbers in italics represent differences that are statistically significant at P \< 0.01.

Experimental approach
---------------------

The experimental approach was to use human whole genome microarray analyses to first identify all genes whose expression was up- or downregulated by butyrate, in a statistically significant manner, by \> two-fold, in the absence of induced DN-Tcf4. We then repeated the analysis in the presence of doxycycline/butyrate-induced DN-Tcf4, and considered those genes whose expression was modulated by butyrate in the absence of doxycycline (intact Wnt signaling) but not similarly modulated in the presence of doxycycline (repressed Wnt signaling). Thus, we were interested in identifying those genes that are differentially expressed (\>two-fold, P \< 0.01) in the NaB vs. Ctrl comparison but not differentially expressed (\>two-fold, P \< 0.01) in the Doxy + NaB vs. Doxy comparison. The NaB vs. Ctrl comparison yields all genes differentially expressed after exposure to 5 mM butyrate, while the Doxy + NaB vs. Doxy comparison yields all butyrate-modulated genes except those that are Wnt activity-targeted, since doxycycline induction combined with butyrate treatment efficiently induces DN-Tcf4 expression (Figure [2](#F2){ref-type="fig"}). Additional information about the experimental design, samples, and raw data are included in Additional files [1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}.

Identification of genes, the expression of which is modulated by butyrate-mediated Wnt signaling
------------------------------------------------------------------------------------------------

Microarray analyses identified a number of genes whose expression levels are modified by butyrate in a manner sensitive to repression of Wnt activity by DN-Tcf4 \[[@B30]\]. Thus, a total of 1008 genes were identified which were modulated by butyrate alone (up- or downregulation) by at least 2-fold with P \< 0.01, and 1587 genes at P \< 0.05, but were not similarly modulated by butyrate when Wnt activity was repressed (induction of DN-Tcf4 by doxycycline and butyrate) (Figure [3](#F3){ref-type="fig"}).

![**Differential expression of genes in NaB vs. Control NOT Doxy + NaB vs. Doxy. (A)** Condition tree. Genes are displayed as normalized to the median expression across 4 samples within each experiment (\>two-fold, paired *T*-test, P \< 0.01, 1008 probes). Red/Orange = Up-regulated relative to median, Yellow = Median expression, Blue = Dn-regulated relative to median. **(B)** Venn diagram emphasizes comparison of NaB vs. Ctrl or Doxy + NaB vs. Doxy (\>two-fold, paired *T*-test, P \< 0.01).](1756-0500-7-226-3){#F3}

Gene ontology analysis of the microarray data reveals a number of functionally relevant gene families, expression of which is influenced by butyrate in a Wnt signaling-dependent manner (Table [2](#T2){ref-type="table"}). These gene families include the **(a)** Biological Process category, such as regulation of development, regulation of metabolism, cytokine and chemokine mediated signaling pathways, and DNA replication; **(b)** Cellular Component category such as cytoskeleton and organelle factors, and intermediate filaments; and **(c)** Molecular Function category, such as GTPase activator activity.

###### 

Microarray data gene ontology classifications

  **Gene ontology**                                                                                                                       
  --------------------------------------------------------------------------------------------------------------- ----------------------- -------------------------------
  **Category** = the name of the category within the ontology.                                                                             
  **Genes in category** = the total number of genes in the genome that have been assigned to the category                                  
  **Genes in list in category** = the total number of genes both in the selected gene list and in the category.                            
  **Biological process**                                                                                                                   
  **Category**                                                                                                    **Genes in category**   **Genes in list in category**
  GO:50769: positive regulation of neurogenesis                                                                   101                     14
  GO:51094: positive regulation of development                                                                    420                     30
  GO:50793: regulation of development                                                                             848                     49
  GO:45598: regulation of fat cell differentiation                                                                59                      9
  GO:50772: positive regulation of axonogenesis                                                                   47                      8
  GO:1779: natural killer cell differentiation                                                                    4                       3
  GO:9991: response to extracellular stimulus                                                                     238                     19
  GO:50767: regulation of neurogenesis                                                                            280                     21
  GO:45600: positive regulation of fat cell differentiation                                                       20                      5
  GO:45444: fat cell differentiation                                                                              126                     12
  GO:30844: positive regulation of intermediate filament depolymerization                                         2                       2
  GO:45108: regulation of intermediate filament polymerization and/or depolymerization                            2                       2
  GO:30842: regulation of intermediate filament depolymerization                                                  2                       2
  GO:45106: intermediate filament depolymerization                                                                2                       2
  GO:45105: intermediate filament polymerization and/or depolymerization                                          2                       2
  GO:48541: Peyer's patch development                                                                             7                       3
  GO:50789: regulation of biological process                                                                      8048                    292
  GO:31667: response to nutrient levels                                                                           211                     16
  GO:1764: neuron migration                                                                                       85                      9
  GO:48537: mucosal-associated lymphoid tissue development                                                        8                       3
  GO:9892: negative regulation of metabolism                                                                      1238                    58
  GO:45595: regulation of cell differentiation                                                                    612                     33
  GO:51093: negative regulation of development                                                                    292                     19
  GO:6066: alcohol metabolism                                                                                     576                     31
  GO:31324: negative regulation of cellular metabolism                                                            1126                    52
  GO:31668: cellular response to extracellular stimulus                                                           64                      7
  GO:30901: midbrain development                                                                                  34                      5
  GO:48715: negative regulation of oligodendrocyte differentiation                                                11                      3
  GO:9912: auditory receptor cell fate commitment                                                                 4                       2
  GO:31670: cellular response to nutrient                                                                         4                       2
  GO:19221: cytokine and chemokine mediated signaling pathway                                                     249                     16
  GO:42423: catecholamine biosynthesis                                                                            24                      4
  GO:1709: cell fate determination                                                                                38                      5
  GO:6260: DNA replication                                                                                        343                     20
  GO:8089: anterograde axon cargo transport                                                                       13                      3
  GO:50768: negative regulation of neurogenesis                                                                   89                      8
  GO:30879: mammary gland development                                                                             39                      5
  GO:45773: positive regulation of axon extension                                                                 25                      4
  GO:45686: negative regulation of glial cell differentiation                                                     25                      4
  GO:17085: response to insecticide                                                                               25                      4
  GO:50770: regulation of axonogenesis                                                                            91                      8
  GO:15879: carnitine transport                                                                                   14                      3
  GO:19800: peptide cross-linking via chondroitin 4-sulfate glycosaminoglycan                                     5                       2
  GO:48732: gland development                                                                                     113                     9
  **Cellular component**                                                                                                                   
  **Category**                                                                                                    **Genes in category**   **Genes in list in category**
  GO:5622: intracellular                                                                                          16495                   558
  GO:43229: intracellular organelle                                                                               13641                   467
  GO:43226: organelle                                                                                             13647                   467
  GO:797: condensin core heterodimer                                                                              2                       2
  GO:43232: intracellular non-membrane-bound organelle                                                            4379                    168
  GO:43228: non-membrane-bound organelle                                                                          4379                    168
  GO:796: condensin complex                                                                                       9                       3
  GO:5856: cytoskeleton                                                                                           2219                    92
  GO:15630: microtubule cytoskeleton                                                                              1021                    48
  GO:5813: centrosome                                                                                             467                     26
  GO:118: histone deacetylase complex                                                                             72                      7
  GO:43231: intracellular membrane-bound organelle                                                                12378                   415
  GO:43227: membrane-bound organelle                                                                              12386                   415
  GO:16272: prefoldin complex                                                                                     14                      3
  GO:31618: nuclear centric heterochromatin                                                                       5                       2
  GO:5882: intermediate filament                                                                                  223                     14
  **Molecular function**                                                                                                                   
  **Category**                                                                                                    **Genes in category**   **Genes in list in category**
  GO:5096: GTPase activator activity                                                                              397                     25
  GO:8118: N-acetyllactosaminide alpha-2,3-sialyltransferase activity                                             3                       2
  GO:16861: intramolecular oxidoreductase activity, interconverting aldoses and ketoses                           11                      3
  GO:4873: asialoglycoprotein receptor activity                                                                   4                       2
  GO:8307: structural constituent of muscle                                                                       70                      7
  GO:8047: enzyme activator activity                                                                              573                     30
  GO:19894: kinesin binding                                                                                       25                      4
  GO:31730: CCR5 chemokine receptor binding                                                                       5                       2
  GO:17123: Ral GTPase activator activity                                                                         5                       2

Clusters of genes whose expression is modulated as described in Figure [3](#F3){ref-type="fig"} and Table [1](#T1){ref-type="table"}, grouped into functionally relevant categories.

Our results are most consistent with the modulation of multiple physiological and cell signaling pathways by butyrate-hyperinduced Wnt activity in CRC cells. These data can be utilized to identify relevant gene targets whose expression can be up- or down-regulated as part of preventive and/or therapeutic approaches against CRC. Further, the array findings can be utilized to better understand the mechanisms behind the physiological effects of butyrate on neoplastic colonic cells, particularly those effects dependent upon modulation of Wnt signaling. In addition, an understanding of Wnt-dependent butyrate-mediated changes in gene expression can inform about the development of butyrate resistance in CRC, which we have shown involves repressed induction of Wnt signaling in the presence of butyrate \[[@B14]\]. Therefore, future studies will be aimed at **(a)** up- or down-regulating relevant genes *in vitro* using overexpression or knockdown strategies, to ascertain effects on cell physiology, including, but not limited to, cell growth, differentiation, and apoptosis, as well as response to butyrate and other HDACis; and **(b)***in vivo* targeted gene overexpression or knockout in murine models of CRC, to evaluate effects on intestinal morphology, tumor formation, and response to dietary or therapeutic interventions, utilizing fiber/butyrate or other HDACis that mimic the effects of butyrate in cell culture \[[@B14]\]. These additional findings can also contribute to the development of more efficacious anti-CRC preventive/therapeutic methodologies.

Conclusions
===========

In summary, this study is the first examination of the total set of direct and indirect Wnt-target genes whose expression is modulated by butyrate in a human CRC cell line. These data suggest a large number of potential gene targets for anti-CRC therapeutic intervention, particularly for those approaches involving fiber/butyrate/HDACis. Knowledge of the molecular mechanisms determining the response of CRC cells to butyrate *in vitro* may assist in determining more effective preventive and therapeutic strategies against CRC.
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